Biodiversity loss is a global and urgent issue.

The 2023 Kew Gardens report found that 45% of the world’s flowering plants face the threat of extinction, more than doubling their estimation in 2016. Reversing this trend is necessary for human flourishing. For one, over 4 billion people rely on herbal medicines as their primary source of healthcare.

The extinction of medical climbing plants—such as Apatophyllum constablei in Australia and Monimopetalum chinense in China—will exacerbate inequality, compel people to switch to potentially harmful artificial medication, and narrow the variety of herbal medicine, which disproportionately affects people with chronic diseases.

Second, the extinction of keystone species creates a ripple effect that is detrimental to the entire ecosystem. Research found that only a handful of plants are depended on to support over 90 percent of plant-eating insects. Thus, private companies in the agricultural and pharmaceutical industries have a growing incentive to join forces with government agencies in tackling the problem of biodiversity loss.

Not only does investing in voluntary Endangered Species Act (ESA) programs reduce the probability or costs of future compliance obligations, but it may also help companies avoid regulation-driven delays and general business uncertainties.

Moreover, governments, incentivized by the national threat posed by biodiversity loss and ecological instability, are pouring funds into adaptive green technology. Consequently, the global green technology market is projected to grow at a yearly growth rate of 24% over the next 9 years, reaching over 112 billion by 2032. This rapidly expanding market allows innovative products like Noah’s Ark to catch the wave and flourish through both direct monetary subsidies and positive policy climates.

Thus, not only would Noah’s Ark address a prominent existential threat facing humanity, but resources are skewed in its favor in the public and private sectors. Together, let’s make a change.